Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mirabegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 18/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.82 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.57 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mirabegron SCHEMBL805237 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL904788 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL1405678 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL15993771 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL15993769 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL1509286 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL16611070 | 0.97 | ADRB3 (0.94) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| SCHEMBL16609366 | 0.90 | ADRB3 (0.81) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| SCHEMBL16609248 | 0.90 | ADRB3 (0.81) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| SCHEMBL11914560 | 0.88 | ADRB3 (0.78) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10149837-B2 | Selective agonists of beta-adrenergic type 3 receptors (BAR3) and use thereof | UNIVERSITA' DEGLI STUDI DI BARI (IT) | 2018-12-11 | — | — | US | claimed |
| EP-3197449-B1 | SELECTIVE AGONISTS OF BETA-ADRENERGIC TYPE 3 RECEPTORS (BAR3) FOR THE TREATMENT OF NEPHROGENIC DIABETES INSIPIDUS | UNIV DEGLI STUDI DI BARI (IT) | 2018-11-21 | — | — | EP | claimed |
| EP-3177589-B1 | METHOD FOR THE SYNTHESIS OF MIRABEGRON AND ITS DERIVATIVES | INTERQUIM SA (ES) | 2018-06-20 | — | — | EP | claimed |
| US-20170296516-A1 | SELECTIVE AGONISTS OF BETA-ADRENERGIC TYPE 3 RECEPTORS (BAR3) AND USE THEREOF | UNIVERSITA' DEGLI STUDI DI BARI (IT) | 2017-10-19 | — | — | US | claimed |
| EP-3197449-A1 | SELECTIVE AGONISTS OF BETA-ADRENERGIC TYPE 3 RECEPTORS (BAR3) AND USE THEREOF | Universita' Degli Studi di Bari (IT) | 2017-08-02 | — | — | EP | claimed |
| EP-3177589-A1 | METHOD FOR THE SYNTHESIS OF MIRABEGRON AND ITS DERIVATIVES | Interquim, S.A. (ES) | 2017-06-14 | — | — | EP | claimed |
| WO-2016046763-A1 | SELECTIVE AGONISTS OF BETA-ADRENERGIC TYPE 3 RECEPTORS (BAR3) AND USE THEREOF | UNIVERSITA' DEGLI STUDI DI BARI (IT) | 2016-03-31 | — | — | WO | claimed |
| WO-2016020440-A1 | METHOD FOR THE SYNTHESIS OF MIRABEGRON AND ITS DERIVATIVES | INTERQUIM, S.A. (ES) | 2016-02-11 | — | — | WO | claimed |
| WO-2015155664-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 2-(2-AMINOTHIAZOL-4-YL)-N-[4-(2-[[(2R)-2-HYDROXY-2- PHENYLETHYL]AMINO]-ETHYL)PHENYL]ACETAMIDE | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-10-15 | — | — | WO | claimed |
| WO-2014132270-A2 | PROCESS FOR THE PREPARATION OF 2-(2-AMINOTHIAZOL-4-YL)-N-[4-(2-{[(2R)-2-HYDROXY-2-PHENYL ETHYL]AMINO}ETHYL)PHENYL]ACETAMIDE MONOHYDROCHLORIDE, ITS INTERMEDIATES AND POLYMORPH THEREOF | MSN LABORATORIES LIMITED (IN) | 2014-09-04 | — | — | WO | claimed |
| WO-2023209440-A1 | METHOD OF EVALUATING SMALL MOLECULE DISTRIBUTION USING TELLUROPHENE ANALOGUES | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2023-11-02 | — | — | WO | disclosed |
| US-20230157962-A1 | NOVEL EXTENDED RELEASE COMPOSITION OF 2-(2- AMINOTHIAZOL-4-YL)-N-[4-(2{[(2R)-2-HYDROXY-2-PHENYLETHYL] AMINO} ETHYL) PHENYL] ACETAMIDE | ZIM LABORATORIES LIMITED (IN) | 2023-05-25 | — | — | US | disclosed |
| WO-2023080855-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MIRABEGRON AND CALCIUM SALTS | SANTA FARMA ILAC SANAYII A.S. (TR) | 2023-05-11 | — | — | WO | disclosed |
| US-11583521-B2 | Long-acting injection dosage form of beta 3 adrenoreceptor agonists | Jubilant Pharma Holdings Inc. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230012402-A1 | LONG-ACTING INJECTION DOSAGE FORM OF BETA 3 ADRENORECEPTOR AGONISTS | Jubilant Pharma Holdings Inc. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-1932838-A2 | Beta-form crystal of acetanilide derivative | Astellas Pharma Inc. (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-7342117-B2 | (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]-acetanilide; free base forms; stability; moisture resistance | ASTELLAS PHARMA INC. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-7342117-B2 | (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]-acetanilide; free base forms; stability; moisture resistance | ASTELLAS PHARMA INC. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20070129435-A1 | Pharmaceutical Composition For Treating Stress Incontinence And/Or Mixed Incontinence | MICHEL MARTIN | 2007-06-07 | — | — | US | disclosed |
| US-20070129435-A1 | Pharmaceutical Composition For Treating Stress Incontinence And/Or Mixed Incontinence | MICHEL MARTIN | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583521-B2 | Long-acting injection dosage form of beta 3 adrenoreceptor agonists | ADRB3, ADRB1, ADRA1B | ADRB3 1/4885ADRB1 2/4885ADRB2 4/4885 |
| US-20070129435-A1 | Pharmaceutical Composition For Treating Stress Incontinence And/Or Mixed Incontinence | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 2/4885 |
| US-20230157962-A1 | NOVEL EXTENDED RELEASE COMPOSITION OF 2-(2- AMINOTHIAZOL-4-YL)-N-[4-(2{[(2R)-2-HYDROXY-2-PHENYLETHYL] AMINO} ETHYL) PHENYL] ACETAMIDE | ADRA2A, ADRB2, ADRA2B | ADRB3 4/4885ADRB1 5/4885ADRB2 2/4885 |
| US-20230012402-A1 | LONG-ACTING INJECTION DOSAGE FORM OF BETA 3 ADRENORECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | ADRB3 1/4885ADRB1 2/4885ADRB2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.